Shield Therapeutics plc (LON:STX – Get Free Report) shares were up 17.6% during mid-day trading on Wednesday . The stock traded as high as GBX 1.60 ($0.02) and last traded at GBX 1.59 ($0.02). Approximately 8,202,623 shares traded hands during trading, an increase of 54% from the average daily volume of 5,333,883 shares. The stock had previously closed at GBX 1.35 ($0.02).
Shield Therapeutics Trading Down 2.4 %
The company has a market cap of £12.59 million, a price-to-earnings ratio of -13.33 and a beta of 0.84. The company has a debt-to-equity ratio of 21.30, a current ratio of 2.95 and a quick ratio of 2.16. The firm’s fifty day moving average price is GBX 1.94 and its 200-day moving average price is GBX 4.76.
About Shield Therapeutics
Shield Therapeutics plc, a specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.
See Also
- Five stocks we like better than Shield Therapeutics
- Stock Dividend Cuts Happen Are You Ready?
- Meta Stock: 3 Reasons This Stumble Is a Golden Buying Opportunity
- Energy and Oil Stocks Explained
- 3 Staples Stocks to Cushion Lower Consumer Sentiment
- What Are Dividends? Buy the Best Dividend Stocks
- Zillow’s Earnings Dip: An Opportunity for Visionaries
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
